Design, synthesis and biological evaluation of Rac1-targeting carbazole-pyrimidines as host-directed antimalarials

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• Antimalarial drug resistance necessitates novel therapeutic strategies.
• Host-directed therapies targeting essential host factors offer a promising alternative.
• The small GTPase Rac1 is a key host factor for Plasmodium falciparum survival.

Purpose of the Study:

• To develop novel carbazole-pyrimidine analogs as inhibitors of host-cell-Rac1 for antimalarial therapy.
• To identify derivatives with improved potency and selectivity against Plasmodium falciparum.
• To validate Rac1 as a viable host target for overcoming drug resistance.

Main Methods:

• Synthesis of a series of carbazole-pyrimidine analogs.
• In vitro antiplasmodial activity testing against chloroquine-sensitive and -resistant strains.
• Cytotoxicity evaluation in human cells to determine selectivity indices.
• Confirmation of Rac1 inhibition in epithelial cells.

Main Results:

• Several derivatives displayed submicromolar inhibitory concentrations against P. falciparum.
• Compounds 11 and 5e emerged as lead candidates with IC50 values of 46.6 nM and 76.0 nM, respectively.
• Lead compounds demonstrated high selectivity indices (>45) and improved potency against resistant strains compared to EHop-016.
• Antimalarial activity was observed throughout the intraerythrocytic developmental cycle.

Conclusions:

• Novel carbazole-pyrimidine derivatives effectively inhibit Plasmodium falciparum growth by targeting host-cell-Rac1.
• Compounds 11 and 5e represent promising lead candidates for developing next-generation antimalarial drugs.
• This study validates Rac1 as a critical host target for effective antimalarial therapies, particularly against resistant strains.